Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H23N5O2S2.CH4O3S |
| Molecular Weight | 585.718 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.O=S(=O)(N1CC2=CC(=CC=C2N(CC3=CN=CN3)C[C@H]1CC4=CC=CC=C4)C#N)C5=CC=CS5
InChI
InChIKey=GQZSWQUMYWWKTN-GNAFDRTKSA-N
InChI=1S/C25H23N5O2S2.CH4O3S/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22;1-5(2,3)4/h1-11,14,18,23H,12,15-17H2,(H,27,28);1H3,(H,2,3,4)/t23-;/m1./s1
Bristol-Myers Squibb developed BMS-214662 as potent and selective farnesyl transferase inhibitor with potent antitumor activity. BMS-214662 participated in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers. However, further information is not available.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Design, Synthesis and Evaluation of Novel 1-(Substituted Acetyl)-4-(10-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine-11-Ylidene)piperidines as Antitumor Agents and Farnesyl Protein Transferase Inhibitors. | 2010-09 |
|
| Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. | 2005-06 |
|
| Targeting RAS signalling pathways in cancer therapy. | 2003-01 |
|
| Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. | 2000-10-05 |
Patents
Sample Use Guides
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
72941825
Created by
admin on Mon Mar 31 18:08:58 GMT 2025 , Edited by admin on Mon Mar 31 18:08:58 GMT 2025
|
PRIMARY | |||
|
DBSALT002162
Created by
admin on Mon Mar 31 18:08:58 GMT 2025 , Edited by admin on Mon Mar 31 18:08:58 GMT 2025
|
PRIMARY | |||
|
CY68RYB4QI
Created by
admin on Mon Mar 31 18:08:58 GMT 2025 , Edited by admin on Mon Mar 31 18:08:58 GMT 2025
|
PRIMARY | |||
|
474010-58-7
Created by
admin on Mon Mar 31 18:08:58 GMT 2025 , Edited by admin on Mon Mar 31 18:08:58 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
